ALDA to Request Human Trials for T36(R) Skin Antiseptic

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)("ALDA") announces that it has
received the final results from BioScience Laboratories, Inc. for the T36(R)
formulation ("T36(R)") tested against 10 different types of viruses. Of these, 5
types were killed within the minimum 30-second time required by the FDA,
including Herpes Types I and II and Influenza B. The remaining 5 types,
including Polio and Hepatitis A, the hardiest viruses, were killed within 1 to 3
minutes.


Successful completion of these tests allows ALDA to approach Health Canada with
a Clinical Trial Application ("CTA") for testing of T36(R) as a skin antiseptic
for surgical use and for personal sanitation. Once the CTA has been approved by
Health Canada, human trials can begin. ALDA can also request a "pre-IND"
(pre-Investigational New Drug) meeting with the FDA for the same indications.
This meeting will determine if any additional tests are required by the FDA
before human trials can begin in the US.


Dr. Terrance Owen, President & CEO, states, "This is an important milestone for
ALDA. Now that ALDA has successfully passed all of the initial microbial tests,
we can advance to the next stage and request human trials for registration of
T36(R) as a skin antiseptic for institutional and consumer use. From our
extensive toxicology studies, we know that T36(R) is very safe, as well as being
very effective. On this basis, we are hoping for a positive outcome from these
meetings."


About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived
from its patented T36(R) technology. The company trades on the TSX Venture
Exchange under the symbol APH.


ALDA Pharmaceuticals Corp.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director